6 months ago
BCRX
AnalystsJonathan WollebenJonathan Wolleben's Stock Forecasts
AnalystsJonathan Wolleben
Analyst Ranking
Top 3%
#135 out of 5269 analysts
Average Return
+20.32%
Win Rate
52%134 out of 258
Risk vs Reward
Poor
Good
Jonathan Wolleben's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Mbx Biosciences IncMBX | +424.08% | $6.27 | $32.86 | 2025-04-10 - 2026-04-09 | Buy |
Dbv Technologies SaDBVT | +408.60% | $4.30 | $21.87 | 2025-03-04 - 2026-03-03 | Buy |
Dbv Technologies SaDBVT | +397.39% | $3.45 | $17.16 | 2024-12-10 - 2025-12-09 | Buy |
Madrigal Pharmaceuticals IncMDGL | +365.01% | $64.44 | $299.65 | 2022-05-10 - 2023-05-09 | Buy |
Dbv Technologies SaDBVT | +242.25% | $4.97 | $17.01 | 2025-01-10 - 2026-01-09 | Buy |
Jonathan Wolleben Analyst Color
Get additional color on Jonathan Wolleben's coverage of popular stocks
7 months ago
BCRX
a year ago
SPOT
Jonathan Wolleben's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Biomea Fusion IncBMEA | 1 | Buy | $9.00 | +492.11% | Initiates Coverage On | 2 days ago |
Dbv Technologies SaDBVT | 18 | Buy | $55.00 | +182.20% | Maintains | 6 days ago |
Opus Genetics IncIRD | 1 | Buy | $12.00 | +130.77% | Initiates Coverage On | 9 days ago |
Crinetics Pharmaceuticals IncCRNX | 20 | Buy | $97.00 | +138.04% | Maintains | 9 days ago |
Mirum Pharmaceuticals IncMIRM | 15 | Buy | $132.00 | +24.75% | Reiterates | 16 days ago |
Kalvista Pharmaceuticals IncKALV | 7 | Buy | $28.00 | +4.83% | Maintains | a month ago |
Rhythm Pharmaceuticals IncRYTM | 9 | Buy | $155.00 | +67.91% | Maintains | 2 months ago |
Spruce Biosciences IncSPRB | 9 | Buy | $170.00 | +186.48% | Maintains | 2 months ago |
Structure Therapeutics IncGPCR | 12 | Buy | $113.00 | +174.94% | Maintains | 2 months ago |
Protagonist Therapeutics IncPTGX | 14 | Buy | $112.00 | +12.89% | Maintains | 2 months ago |
Sionna Therapeutics IncSION | 1 | Buy | $63.00 | +53.77% | Initiates Coverage On | 2 months ago |
Madrigal Pharmaceuticals IncMDGL | 13 | Buy | $745.00 | +48.27% | Maintains | 4 months ago |
Sagimet Biosciences IncSGMT | 9 | Buy | $35.00 | +353.37% | Maintains | 6 months ago |
Savara IncSVRA | 10 | Buy | $10.00 | +90.48% | Maintains | 6 months ago |
Altimmune IncALT | 13 | Buy | $14.00 | +357.52% | Maintains | 6 months ago |
Biocryst Pharmaceuticals IncBCRX | 10 | Buy | $25.00 | +176.85% | Maintains | 6 months ago |
Kalaris Therapeutics IncKLRS | 1 | Buy | $20.00 | +277.36% | Initiates Coverage On | 6 months ago |
Ocular Therapeutix IncOCUL | 16 | Buy | $29.00 | +198.66% | Maintains | 7 months ago |
Larimar Therapeutics IncLRMR | 13 | Buy | $18.00 | +348.88% | Reiterates | 9 months ago |
Pharvaris NvPHVS | 12 | Buy | $52.00 | +73.22% | Maintains | 9 months ago |
Astria Therapeutics IncATXS | 3 | Buy | $26.00 | +106.68% | Maintains | 9 months ago |
Quince Therapeutics IncQNCX | 2 | Buy | $80.00 | +6,404.07% | Maintains | 9 months ago |
Proqr Therapeutics NvPRQR | 6 | Buy | $8.00 | +390.80% | Reiterates | 10 months ago |
Skye Bioscience IncSKYE | 3 | Buy | $15.00 | +1,610.38% | Reiterates | 10 months ago |
Aura Biosciences IncAURA | 9 | Buy | $19.00 | +113.48% | Reiterates | a year ago |
Clearside Biomedical IncCLSDQ | 11 | Buy | $75.00 | +18,192.68% | Reiterates | a year ago |
Mbx Biosciences IncMBX | 1 | Buy | $38.00 | N/A | Initiates Coverage On | a year ago |
Hilton Grand Vacations IncHGV | 1 | Buy | $50.00 | N/A | Maintains | a year ago |
Costar Group IncCSGP | 1 | Buy | $90.00 | N/A | Reiterates | a year ago |
Spotify Technology SaSPOT | 1 | Buy | $485.00 | N/A | Downgrades | a year ago |
Allakos IncALLK | 6 | Buy | $3.00 | N/A | Reiterates | 2 years ago |
Rallybio CorpRLYB | 11 | Buy | $64.00 | N/A | Reiterates | 2 years ago |
Warner Music Group CorpWMG | 1 | Buy | $24.00 | N/A | Maintains | 3 years ago |
Strongbridge Biopharma PLCSBBP | 1 | Hold | N/A | N/A | Downgrades | 5 years ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.